<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002571</url>
  </required_header>
  <id_info>
    <org_study_id>V01-124A-301</org_study_id>
    <nct_id>NCT03002571</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of IDP-124 Lotion</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic&#xD;
      Dermatitis in Pediatric and Adult Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Efficacy&#xD;
      and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in&#xD;
      Pediatric and Adult Subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2018</start_date>
  <completion_date type="Actual">April 14, 2020</completion_date>
  <primary_completion_date type="Actual">April 14, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Variable is the IGA (Investigator's Global Assessment) score at Week 6.</measure>
    <time_frame>6 Weeks</time_frame>
    <description>Success is defined as achieving clear to almost clear (i.e., a score of 0 or 1) and at least a 2-grade improvement in the IGA score at the end of treatment compared with Baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>IDP-124 Lotion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-124 Vehicle Lotion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-124 Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>IDP-124 Lotion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-124 Vehicle Lotion</intervention_name>
    <description>Lotion</description>
    <arm_group_label>IDP-124 Vehicle Lotion</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at least 2 years of age and older&#xD;
&#xD;
          -  Written and verbal informed consent must be obtained; subjects less than age of&#xD;
             consent must sign an assent for the study and a parent or a legal guardian must sign&#xD;
             the informed consent (if subject reaches age of consent during the study they should&#xD;
             be re-consented at the next study visit)&#xD;
&#xD;
          -  Nonimmunocompromized male or female who failed to respond adequately to other topical&#xD;
             prescription treatment for AD or for whom those treatments are not advisable&#xD;
&#xD;
          -  Subjects must be willing to comply with study instructions and return to the clinic&#xD;
             for required visits; subjects under the age of consent must be accompanied by the&#xD;
             parent or legal guardian at the time of assent/consent signing&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, breast feeding, or who wish to become pregnant during the&#xD;
             study period&#xD;
&#xD;
          -  Active cutaneous bacterial or viral infection in any treatment area at Baseline (eg,&#xD;
             clinically infected AD)&#xD;
&#xD;
          -  Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at Baseline,&#xD;
             which would interfere with evaluations&#xD;
&#xD;
          -  History of confounding skin conditions, eg, psoriasis, rosacea, erythroderma, or&#xD;
             ichthyosis (other than ichthyosis vulgaris)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binu Alexander, MD</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 21, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <disposition_first_submitted>April 12, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>April 12, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 13, 2021</disposition_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

